ROCHE DIAGNOSTICS LIMITED

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

1. ROCHE DIAGNOSTICS LIMITED 1998-04-22 → present
2. BOEHRINGER MANNHEIM UK HOLDINGS LIMITED 1997-03-01 → 1998-04-22
3. BOEHRINGER MANNHEIM UK (PHARMACEUTICALS) LIMITED 1989-12-19 → 1997-03-01
4. M.C.P.PHARMACEUTICALS LIMITED 1956-09-14 → 1989-12-19

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

KPMG LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have prepared the financial statements on the going concern basis as they do not intend to liquidate the Company or to cease its operations, and as they have concluded that the Company's financial position means that this is realistic. They have also concluded that there are no material uncertainties that could have cast significant doubt over its ability to continue as a going concern for at least a year from the date of approval of the financial statements”

Group structure

1. ROCHE DIAGNOSTICS LIMITED · parent
   1. AVL Medical Instruments UK Limited 100% · UK
   2. Ventana Medical Systems Limited 100% · UK
   3. LumiraDx UK Limited 100% · UK
   4. Lumira Dx Proprietary Limited 100% · South Africa
   5. LKM Innovations Ltd 100% · UK

Significant events

• “As of 31 December 2024 the Company acquired the assets of Roche Diabetes Care Limited as part of a global project to integrate the divisions of Diagnostics and Diabetes Care, under the project called "Fusion". The project was part of a global proposal to simplify the Group's corporate structure, and was undertaken with the aim of consolidating activities”
• “The company acquired LumiraDx Group companies held by LumiraDx Group Limited (in administration) and LumiraDx International Limited (in administration) on 26 July 2024 to compliment its Diagnostics portfolio to support patients with improved testing in the primary care environment. The cost of the acquisition was $244,210,823 (£190,010,366) and it was recognised as an investment in subsidiaries on the balance sheet in 2024.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

0

last 24 months

Officers appointed

3

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +3.1%

  £333,038,000 → £343,516,000

• Cash

  -45%

  £818,000 → £450,000

• Net assets

  +2.1%

  £134,563,000 → £137,389,000

• Employees

  +5.3%

  723 → 761

• Operating profit

  +7.6%

  £15,932,000 → £17,141,000

• Profit before tax

  -36.2%

  £11,474,000 → £7,320,000

• Wages

  +5%

  £54,124,000 → £56,827,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers